At Bristol Myers Squibb, we are inspired by a single vision transforming patients lives through science. In oncology, hematology, immunology and cardiovascular disease and one of the most diverse and promising pipelines in the industry each of our passionate colleagues contribute to innovations that drive meaningful change. We bring a human touch to every treatment we pioneer. Join us and make a difference.
The candidate will have responsibility for directing the scientific aspects of drug development programs and translational medicine correlative studies in Immune Oncology and Cellular Therapy Thematic Research Center. The successful candidate will be responsible for driving and implementing translational development strategies for BMSs drugs. Expertise in developing biomarkers for clinical trials, and strong knowledge in immunology and tumor biology, is required. The individual will work with contract research organizations, and internal and external collaborators, to design, execute, and interpret translationally focused experiments. Activities include biomarker identification, assay validation and implementation, and generation of data that supports patient stratification and pharmacodynamic evaluation of drugs and mechanism of action in the clinical trial setting. Candidates with experience in cellular therapies desirable.
Responsibilities:
* In-depth knowledge of immunology, immune oncology, and tumor biology in solid and hematological malignancies
* Develop new concepts and mechanism of action hypotheses identifying distinguishing characteristic of BMS IO and cell therapy agents alone and in combination with other therapies by utilizing translational medicine-based approaches.
* Biomarker discovery and development: assay development/validation, discovery of biomarkers for clinical trial use, MoA research, knowledge of platforms
* Manage internal projects in immune oncology and cell therapy drug development
* Serve on internal cross functional project teams and committees as scientific functional lead
* Work closely with corporate partners to support preclinical, translational and clinical development of cancer therapeutics.
* Understand the context, impact and timely communication of data
* Coordination of external academic collaborations and contract research laboratories
Specific Duties:
* Develop and direct in-vitro and ex-vivo assays to translate preclinical data into meaningful clinical biomarkers for advancing drug candidates through clinical trials
* Coordinate analysis of clinical trial samples and drive interpretation of pharmacodynamic and MoA biomarkers
* Critically analyze, interpret, report experimental results; draw appropriate conclusions and design next steps
* Participate in project and program team meetings to present data and provide interpretation
* Establish and maintain working relationship with contract laboratories and relevant academic collaborators
* Ensure that the Immune Oncology group maintains current awareness in area of expertise, and enhance the scientific credibility of BMS through contributions to the scientific literature (publications/presentations)
* Contribute to the writing of investigator brochures, IND/BLA/MAA applications, regulatory annual reports, clinical trial protocols, and other regulatory documents when appropriate
Qualifications:
* Ph.D.Degree in immunology, tumor biology or molecular or cellular biology, Ph.D. with successful experience as a scientist preferably in the biotechnology or pharmaceutical industry setting
* Expertise in developing and analyzing biomarkers for clinical trials desired
* Relevant skills include proficiency in immunological techniques (flow cytometry, intracellular staining, cytotoxicity assays, ELISA, ELISpot, etc.), cell biology (transient and stable engineering of cell lines, also using viral transduction, immunocytochemistry, microscopy), and molecular biology
* Excellent communication and interpersonal skills, evidenced by strong ability to interact with and manage research scientists, project teams, outside collaborators and commercial vendors
* Detail-oriented with the ability to identify and implement creative solutions
* Ability to prioritize and manage time efficiently
* Ability to work effectively and collaboratively in a highly matrixed organization
BMSCART
Around the world, we are passionate about making an impact on the lives of patients with serious diseases. Empowered to apply our individual talents and diverse perspectives in an inclusive culture, our shared values of passion, innovation, urgency, accountability, inclusion and integrity bring out the highest potential of each of our colleagues.
Bristol Myers Squibb recognizes the importance of balance and flexibility in our work environment. We offer a wide variety of competitive benefits, services and programs that provide our employees with the resources to pursue their goals, both at work and in their personal lives.
New York, New York
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. The company offers drugs in oncology, immunoscience, cardiovascular, and fibrotic diseases. The company’s products include Opdivo, a biological product for anti-cancer indications; Eliquis, an oral inhibitor targeted at stroke prevention in adult patients with non-valvular atrial fibrillation, and the prevention and treatment of venous thromboembolic disorders; and Orencia, a biological product for adult patients with moderately to severely active RA and prostate-specific antigen, as well as reducing signs and symptoms in certain pediatric patients with moderately to severely active polyarticular juvenile idiopathic arthritis.
It also provides Sprycel, a tyrosine kinase inhibitor for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, a monoclonal antibody for the treatment of patients with unresectable or metastatic melanoma; Empliciti, a humanized monoclonal antibody for the treatment of multiple myeloma; and Baraclude, an oral antiviral agent for the treatment of chronic hepatitis B. In addition, the company offers Reyataz, a protease inhibitor for the treatment of human immunodeficiency virus (HIV) and Evotaz; Sustiva franchise, a non-nucleoside reverse transcriptase inhibitor for the treatment of HIV; and Daklinza NS5A replication complex inhibitor, Sunvepra NS3 protease inhibitor, and Beclabuvir NS5B inhibitor. It sells products to wholesalers, retail pharmacies, hospitals, government entities, and medical profession. It has collaboration agreements with Nektar Therapeutics; Janssen Pharmaceuticals, Inc.; Biocartis Group NV.; and FameWave Ltd.
The company was formerly known as Bristol-Myers Company and changed its name to Bristol-Myers Squibb Company in 1989. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in New York, New York.